Aptose Biosciences INC 8-K filings

Aptose Biosciences has entered into a Cooperative Research and Development Agreement with the National Cancer Institute to further develop tuspetinib for AML and MDS through the myeloMATCH precision medicine trials.

Aptose Biosciences has successfully closed an $8 million public offering, issuing common shares and warrants to fund working capital and general corporate activities.

Aptose Biosciences has announced the pricing of an $8 million public offering of common stock and warrants.

Aptose Biosciences has commenced the TUSCANY Phase 1/2 study, evaluating tuspetinib in combination with azacitidine and venetoclax as a frontline treatment for newly diagnosed acute myeloid leukemia (AML) patients.

Aptose Biosciences announced its third-quarter 2024 financial results, highlighted by a $10 million loan from Hanmi Pharmaceutical and ongoing development of its lead drug, tuspetinib, while also addressing Nasdaq listing compliance issues.

Aptose Biosciences has received a delisting notice from Nasdaq after failing to meet the minimum stockholders' equity requirement, and intends to appeal the decision.

Aptose Biosciences Inc. shareholders voted to authorize the issuance of warrant shares and approved a measure to adjourn the meeting if necessary.

Aptose Biosciences announced the successful passage of two key proposals at its special shareholder meeting, including approval for a Nasdaq share issuance and meeting adjournments.

Aptose Biosciences has entered into a $10 million loan agreement with Hanmi Pharmaceutical, with potential for conversion into a future collaboration agreement for the development of tuspetinib.

Aptose Biosciences has adjourned its special shareholder meeting to September 5th due to insufficient shareholder representation, despite having enough proxy votes to pass all resolutions.

Aptose Biosciences reported its Q2 2024 financial results and provided a corporate update, highlighting the FDA's approval to proceed with a triplet therapy study for its drug tuspetinib.

Aptose Biosciences is initiating a Phase 1/2 trial of Tuspetinib in combination with Venetoclax and a hypomethylating agent (HMA) as a frontline therapy for newly diagnosed Acute Myeloid Leukemia (AML).

Aptose Biosciences has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, but the stock will continue to trade on the exchange while the company works to regain compliance.

Aptose Biosciences Inc. held its Annual and Special Meeting of Shareholders on June 18, 2024, where all proposed items were approved by shareholders.

Aptose Biosciences reports the re-election of all director nominees and approval of key proposals at its annual and special shareholder meeting.

Aptose Biosciences presented clinical and preclinical data at the European Hematology Association (EHA) 2024 Congress, showcasing the broad activity and safety of Tuspetinib (TUS) as a monotherapy and in combination with Venetoclax (VEN) for treating Acute Myeloid Leukemia (AML).

Aptose Biosciences has successfully closed a $4.43 million registered direct offering, priced at-the-market, to fund working capital and general corporate purposes.

Aptose Biosciences has entered into a securities purchase agreement for a direct offering and private placement, raising approximately $4.43 million.

Aptose Biosciences has entered into a definitive agreement for a $4.43 million registered direct offering and terminated its equity distribution agreement with JonesTrading.

Aptose Biosciences reports first quarter 2024 results and announces the advancement of its drug tuspetinib to a frontline triplet therapy for newly diagnosed acute myeloid leukemia (AML).

Aptose Biosciences will release its first quarter 2024 financial results and provide a clinical strategy update on May 14, 2024.

Aptose Biosciences has amended the employment agreements of its top executives to align change of control provisions and adjust base salaries.

Aptose Biosciences amended its warrant agreement with Hanmi Pharmaceutical to comply with Nasdaq listing rules regarding share issuance limits.

Aptose Biosciences received a notification from Nasdaq for not meeting the minimum stockholders' equity requirement, but the company plans to submit a compliance plan.

Aptose Biosciences announced its 2023 financial results and provided a corporate update, highlighting the advancement of tuspetinib to a triplet therapy pilot study in frontline AML.

Aptose Biosciences will release its fourth quarter and year-end 2023 financial results and provide a corporate update on March 26, 2024.

Aptose Biosciences received a deficiency letter from Nasdaq for issuing shares to Hanmi Pharmaceutical without prior shareholder approval, potentially leading to delisting.

Aptose Biosciences successfully closed a public offering and private placement, raising approximately $13.7 million to support clinical trials and general corporate purposes.

Aptose Biosciences has entered into agreements to raise approximately $13 million through a public offering and a private placement with Hanmi Pharmaceutical.

Aptose Biosciences has announced an $8.4 million public offering and a concurrent $4 million private placement with Hanmi Pharmaceutical to fund clinical trials and working capital.